Similar articles for PMID: 28198380

Year	Number of Results
2001	1
2002	1
2008	1
2010	2
2011	1
2012	4
2013	4
2014	8
2015	15
2016	22
2017	25
2018	12
2019	13
2020	21
2021	16
2022	5
2023	4
2024	0

1

A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.

Rane C, Senapedis W, Baloglu E, Landesman Y, Crochiere M, Das-Gupta S, Minden A. Rane C, et al. Sci Rep. 2017 Feb 15;7:42555. doi: 10.1038/srep42555. Sci Rep. 2017. PMID: 28198380 Free PMC article.

2

KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.

Cordover E, Wei J, Patel C, Shan NL, Gionco J, Sargsyan D, Wu R, Cai L, Kong AN, Jacinto E, Minden A. Cordover E, et al. Chem Res Toxicol. 2020 Feb 17;33(2):482-491. doi: 10.1021/acs.chemrestox.9b00376. Epub 2020 Jan 9. Chem Res Toxicol. 2020. PMID: 31876149 Free PMC article.

3

Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.

Abu Aboud O, Chen CH, Senapedis W, Baloglu E, Argueta C, Weiss RH. Abu Aboud O, et al. Mol Cancer Ther. 2016 Sep;15(9):2119-29. doi: 10.1158/1535-7163.MCT-16-0197. Epub 2016 Jul 7. Mol Cancer Ther. 2016. PMID: 27390344 Free PMC article.

4

Targeting the vulnerability to NAD⁺ depletion in B-cell acute lymphoblastic leukemia.

Takao S, Chien W, Madan V, Lin DC, Ding LW, Sun QY, Mayakonda A, Sudo M, Xu L, Chen Y, Jiang YY, Gery S, Lill M, Park E, Senapedis W, Baloglu E, Müschen M, Koeffler HP. Takao S, et al. Leukemia. 2018 Mar;32(3):616-625. doi: 10.1038/leu.2017.281. Epub 2017 Sep 14. Leukemia. 2018. PMID: 28904384

5

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.

Li N, Lopez MA, Linares M, Kumar S, Oliva S, Martinez-Lopez J, Xu L, Xu Y, Perini T, Senapedis W, Baloglu E, Shammas MA, Hunter Z, Anderson KC, Treon SP, Munshi NC, Fulciniti M. Li N, et al. Clin Cancer Res. 2019 Jan 1;25(1):369-377. doi: 10.1158/1078-0432.CCR-18-1776. Epub 2018 Sep 11. Clin Cancer Res. 2019. PMID: 30206161 Free PMC article.

6

Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.

Hwang VJ, Zhou X, Chen X, Trott J, Abu Aboud O, Shim K, Dionne LK, Chmiel KJ, Senapedis W, Baloglu E, Mahjoub MR, Li X, Weiss RH. Hwang VJ, et al. Kidney Int. 2017 Oct;92(4):922-933. doi: 10.1016/j.kint.2017.03.031. Epub 2017 May 23. Kidney Int. 2017. PMID: 28545714 Free PMC article.

7

Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation.

Arowosegbe MA, Amusan OT, Adeola SA, Adu OB, Akinola IA, Ogungbe BF, Omotuyi OI, Saibu GM, Ogunleye AJ, Kanmodi RI, Lugbe NE, Ogunmola OJ, Ajayi DC, Ogun SO, Oyende FO, Bello AO, Ishola PG, Obasieke PE. Arowosegbe MA, et al. Curr Drug Discov Technol. 2020;17(5):682-695. doi: 10.2174/1570163816666190823135948. Curr Drug Discov Technol. 2020. PMID: 31441728

8

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.

Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS. Aboukameel A, et al. Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. Epub 2016 Nov 15. Mol Cancer Ther. 2017. PMID: 28062705 Free PMC article.

9

Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.

Dasgupta A, Sierra L, Tsang SV, Kurenbekova L, Patel T, Rajapakse K, Shuck RL, Rainusso N, Landesman Y, Unger T, Coarfa C, Yustein JT. Dasgupta A, et al. Cancer Res. 2021 Jan 1;81(1):199-212. doi: 10.1158/0008-5472.CAN-20-0854. Epub 2020 Nov 9. Cancer Res. 2021. PMID: 33168646 Free PMC article.

10

PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.

Mpilla GB, Uddin MH, Al-Hallak MN, Aboukameel A, Li Y, Kim SH, Beydoun R, Dyson G, Baloglu E, Senapedis WT, Landesman Y, Wagner KU, Viola NT, El-Rayes BF, Philip PA, Mohammad RM, Azmi AS. Mpilla GB, et al. Mol Cancer Ther. 2021 Oct;20(10):1836-1845. doi: 10.1158/1535-7163.MCT-20-1105. Epub 2021 Jul 12. Mol Cancer Ther. 2021. PMID: 34253597 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

141 results

Results by year